Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 fluorescence endoscopy in suspected T1/HGD rectal polyps
NL-OMON59512Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sgm-101 in rectal cancer, rectal adenocarcinoma and conventional adenoma (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Ex-vivo NIR-fluorescence TDR on bread loafs and pathology slides. Started Dec 2023; status: completed.
02
Drugs
sgm-101
03
Conditions
rectal cancerrectal adenocarcinomaconventional adenoma
Beyond the preview
Go deeper on NL-OMON59512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59512.